Halozyme Therapeutics, Inc. (NASDAQ:HALO) Holdings Cut by Alliancebernstein L.P.

Alliancebernstein L.P. cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 3,068,432 shares of the biopharmaceutical company's stock after selling 339,909 shares during the period. Alliancebernstein L.P. owned 2.41% of Halozyme Therapeutics worth $146,702,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Halozyme Therapeutics by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after purchasing an additional 386,618 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Halozyme Therapeutics by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company's stock worth $175,194,000 after acquiring an additional 30,901 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock worth $85,254,000 after acquiring an additional 9,780 shares during the last quarter. Norges Bank purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $60,054,000. Finally, Arrowstreet Capital Limited Partnership increased its position in Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock worth $47,470,000 after purchasing an additional 581,475 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Remove Ads

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey William Henderson sold 503 shares of the business's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the completion of the sale, the director now directly owns 33,108 shares of the company's stock, valued at approximately $2,120,567.40. This represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,200 shares of company stock worth $1,786,668 in the last 90 days. 2.90% of the stock is owned by corporate insiders.

Halozyme Therapeutics Stock Down 3.5 %

Shares of HALO traded down $2.15 during mid-day trading on Friday, reaching $59.77. 2,295,325 shares of the stock traded hands, compared to its average volume of 1,393,194. The firm has a market cap of $7.38 billion, a price-to-earnings ratio of 17.43, a P/E/G ratio of 0.42 and a beta of 1.32. The stock has a fifty day simple moving average of $59.82 and a 200 day simple moving average of $54.93. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Benchmark reissued a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Piper Sandler raised their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Finally, Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.